ANI Pharmaceuticals Management
Management criteria checks 3/4
ANI Pharmaceuticals' CEO is Nikhil Lalwani, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $8.08M, comprised of 9.5% salary and 90.5% bonuses, including company stock and options. directly owns 1.92% of the company’s shares, worth €20.08M. The average tenure of the management team and the board of directors is 3 years and 4.2 years respectively.
Key information
Nikhil Lalwani
Chief executive officer
US$8.1m
Total compensation
CEO salary percentage | 9.5% |
CEO tenure | 4.2yrs |
CEO ownership | 1.9% |
Management average tenure | 3yrs |
Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | US$23m |
Mar 31 2024 | n/a | n/a | US$31m |
Dec 31 2023 | US$8m | US$764k | US$15m |
Sep 30 2023 | n/a | n/a | US$10m |
Jun 30 2023 | n/a | n/a | -US$8m |
Mar 31 2023 | n/a | n/a | -US$28m |
Dec 31 2022 | US$5m | US$737k | -US$50m |
Sep 30 2022 | n/a | n/a | -US$69m |
Jun 30 2022 | n/a | n/a | -US$65m |
Mar 31 2022 | n/a | n/a | -US$63m |
Dec 31 2021 | US$7m | US$715k | -US$43m |
Sep 30 2021 | n/a | n/a | -US$22m |
Jun 30 2021 | n/a | n/a | -US$17m |
Mar 31 2021 | n/a | n/a | -US$15m |
Dec 31 2020 | US$4m | US$199k | -US$23m |
Compensation vs Market: Nikhil's total compensation ($USD8.08M) is above average for companies of similar size in the German market ($USD1.44M).
Compensation vs Earnings: Nikhil's compensation has been consistent with company performance over the past year.
CEO
Nikhil Lalwani (46 yo)
4.2yrs
Tenure
US$8,078,353
Compensation
Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.2yrs | US$8.08m | 1.92% € 20.1m | |
Senior VP of Finance & CFO | 8.5yrs | US$2.58m | 0.83% € 8.7m | |
Senior Vice President of Corporate Development & Strategy | 3yrs | US$1.90m | 1.24% € 13.0m | |
Senior Vp & Head of Rare Disease | 3.8yrs | US$1.91m | 0.43% € 4.5m | |
Senior Vice President of Generics | 3.8yrs | US$1.94m | 0.40% € 4.1m | |
Head of R&D | 3yrs | no data | 0.26% € 2.7m | |
Senior Vice President of Operations | 8.5yrs | US$1.43m | 0.60% € 6.3m | |
Chief Compliance Officer & Head of Legal of Rare Disease | 2.8yrs | no data | no data | |
Senior VP | 2.3yrs | no data | 0.29% € 3.0m | |
Senior VP & Chief Human Resources Officer | 2.2yrs | no data | 0.26% € 2.7m | |
Chief Medical Officer | 2.8yrs | no data | no data | |
Senior VP & Head of Established Brands | 3yrs | no data | 0.17% € 1.8m |
3.0yrs
Average Tenure
51.5yo
Average Age
Experienced Management: BSFA's management team is considered experienced (3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.2yrs | US$8.08m | 1.92% € 20.1m | |
Head of R&D | 3yrs | no data | 0.26% € 2.7m | |
Independent Chairman | 6.5yrs | US$422.21k | 0.38% € 4.0m | |
Independent Director | 4.3yrs | US$393.25k | 0.16% € 1.7m | |
Independent Director | 6.5yrs | US$412.21k | 0.26% € 2.8m | |
Independent Director | 4.3yrs | US$395.75k | 0.21% € 2.2m | |
Independent Director | 2.7yrs | US$392.37k | 0.12% € 1.2m | |
Independent Director | 1.3yrs | US$470.76k | 0.061% € 644.0k |
4.2yrs
Average Tenure
61.5yo
Average Age
Experienced Board: BSFA's board of directors are considered experienced (4.2 years average tenure).